Regulation

ArteraAI Prostate analyzes digital pathology images of a prostate cancer biopsy slide to help clinicians predict long-term outcomes.

The Swiss company’s over-the-counter wrist wearable, which uses optical sensors to gather blood pressure readings, will be available to U.S. consumers in 2026.

The wristband is designed to alleviate essential tremors by modulating the nervous system and restoring motor control.

Michael Needham, principal at Efficio, says the Trump administration's tariffs create uncertainty and indecision for business.  

Independent accreditation is essential to ensure that health technology and health organizations are compliant with HIPAA, NIST and other standards, says Kathryn Ayers Wickenhauser, DirectTrust's chief strategy officer.

Also, fellow Korean medical AI companies have obtained regulatory approvals across global markets. 

While the change of administration means federal regulations and funding remain in flux, PointClickCare's Brian Drozdowicz believes healthcare vendors and organizations are making strides in improving interoperability.

Jonathan French, HIMSS' senior director of public policy, lays out the key points of HIMSS' response to the White House's request for information from the public on developing an AI action plan.

Michael Ramey, managing principal of Strategic & Transaction Solutions at PYA says due to changes in the FTC's new premerger notification rules, he's advising clients to be prepared to disclose more information and undergo greater scrutiny.